Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose
March 19 2021 - 10:30AM
Business Wire
- Far reaching implications for ease of widescale distribution
and administration anytime, anywhere
- Better candidate for protection against COVID-19 variants due
to triple antigen targeting
- Oravax Medical Inc. established to accelerate vaccine’s path to
market
- Clinical trials expected to commence Q2 2021
Premas Biotech, a developer of novel biotherapeutic and vaccine
candidates, announced today the development of an oral COVID-19
vaccine that has shown efficacy after a single dose, in conjunction
with Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210319005359/en/
Accelerating the vaccine’s path to market, Premas, Oramed and
other shareholders, have formed Oravax Medical Inc. which has
received exclusive licenses from Oramed and Premas to develop oral
COVID-19 vaccines.
After a single dose of the Oravax COVID-19 capsule, efficacy was
evident through antibody production in a pilot animal study.
Oravax’s vaccine promoted both systemic immunity through
Immunoglobulin G (IgG), the most common antibody in blood and
bodily fluids that protects against viral infections, and
Immunoglobulin A (IgA) which protects the respiratory and
gastrointestinal tracts against infection.
Premas’ protein-based VLP (Virus Like Particle) vaccine
candidate creates triple protection against the SARS CoV-2 virus
Spike, Membrane, and Envelope targets. The vaccine candidate is
also safe, efficacious and well tolerated at normal to high doses,
and generated high titres of neutralizing antibodies. The VLP is
manufactured using Premas’ proprietary D-Crypt™ platform, which is
highly scalable and can be manufactured on large scales.
Premas Biotech Co-Founder and Managing Director Dr. Prabuddha
Kundu commented, “An oral COVID-19 vaccine that harnesses and
combines the true potential of the two platforms, Premas’ D-Crypt™
technology platform with Oramed’s world-leading oral protein
delivery platform POD® is an excellent example of a true
collaboration and can rapidly advance into late-stage clinical
trials. Oramed’s experience and success in conducting Phase 2 and 3
oral protein trials positions our program very favorably in the
race to find an effective oral COVID-19 vaccine that can be
administered by anyone anywhere. We are looking forward to sharing
clinical data soon.”
“We are very excited about our oral vaccine candidate’s
potential to help end the pandemic,” said Nadav Kidron, CEO of
Oramed. “An oral COVID-19 vaccine would eliminate several barriers
to rapid, widescale distribution, enabling people to take the
vaccine themselves at home. While ease of administration is
critical today to accelerate inoculation rates, an oral vaccine
could become even more valuable in the likely case that a COVID-19
vaccine may be required annually or biannually like the standard
flu shot.”
About Oravax Medical Inc.
Oravax was established in 2021 by Oramed Pharmaceuticals Inc.,
the largest shareholder in Oravax, along with Premas Biotech and
certain other shareholders with a mission to bring an oral COVID-19
vaccine to the market. Oravax combines cutting edge vaccine
technology acquired from Premas Biotech and the proprietary POD™
oral delivery technology of Oramed Pharmaceuticals. For more
information, please visit www.ora-vax.com
About Premas Biotech
Premas Biotech develops novel technologies and partners with
global biopharmaceutical companies to build and develop novel
biotherapeutic & vaccine candidates. Premas' key focus areas
are infectious diseases, cancer, metabolic disorders and
inflammation. Besides D-Crypt™ the difficult to express proteins
expression platform, Premas’ leading technologies include
Axtex-4D™: an ex-vivo tissueoid generation platform and C-Qwence™:
a fully human naive India based scFv antibody library. Further
information is available on the Company’s website:
www.premasbiotech.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210319005359/en/
Ambar Mehrotra Mobile: +91 89684 82266 Ph: +91-124-454 6600
contact@premasbiotech.com
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Sep 2023 to Sep 2024